Future Research
Invest In Our Projects
The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years
Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher expression of IL13RA2 in DIPG cells versus normal cancer cells. We have also shown IL13RA2 is highly expressed at the protein level across multiple DIPG samples from cancer patients, confirming
Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years
Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis? The major goal of this project is to test the hypothesis that IL4Rα blockade will prevent new soft tissue sarcoma engraftment, metastases and relapse by interfering with tumor cell – muscle stem cell interactions and thus represent
Marizomib in Medulloblastoma: $240,000 over 2 years
The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.
CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually
Be the sponsor of this project! One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research by improving model systems for pediatric diseases. To this end, we have developed a Legacy Gift (research autopsy) program called the Cancer Registry for Familial and Sporadic Tumors (CUREfast) to
Synthetic Human 2.1 — Empowering the Surgeon: $160,000 over one year
Alveolar rhabdomyosarcoma is a cancer of the soft tissues. Local control for rhabdomyosarcoma is an important clinical challenge, and recurrence at the tumor resection bed can be a gateway to progression and metastasis. Our project seeks to put the types of cutting edge, non-chemotherapy medicines used by internists into the hands of the surgeon for the purpose of preventing local recurrence at the earliest possible moment.
Engineering Forward Initiative for Childhood Cancer Therapies: $1,500,000
This multi-disciplinary approach to accelerating discovery of therapies for childhood cancer is made possible by a joint effort of our scientific director Dr. Keller and our Board member, Sunit Rikhi, former VP of the Intel custom foundry. Together, our teams of biologists and engineers will maximize automation and the design of new devices and biomaterials that address challenges in the treatment of cancer as well as prevention of recurrence, ultimately improving outcomes for children with cancer.
A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually
Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical: for tumors in a limb, local control permits limb-sparing procedures; whereas for tumors not in a limb, local control can mean the difference between cure and progression of disease. Our recent published studies suggest that a non-chemotherapy medicine
The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years
Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher expression of IL13RA2 in DIPG cells versus normal cancer cells. We have also shown IL13RA2 is highly expressed at the protein level across multiple DIPG samples from cancer patients, confirming
Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years
Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis? The major goal of this project is to test the hypothesis that IL4Rα blockade will prevent new soft tissue sarcoma engraftment, metastases and relapse by interfering with tumor cell – muscle stem cell interactions and thus represent
Marizomib in Medulloblastoma: $240,000 over 2 years
The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.
CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually
Be the sponsor of this project! One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research by improving model systems for pediatric diseases. To this end, we have developed a Legacy Gift (research autopsy) program called the Cancer Registry for Familial and Sporadic Tumors (CUREfast) to
Synthetic Human 2.1 — Empowering the Surgeon: $160,000 over one year
Alveolar rhabdomyosarcoma is a cancer of the soft tissues. Local control for rhabdomyosarcoma is an important clinical challenge, and recurrence at the tumor resection bed can be a gateway to progression and metastasis. Our project seeks to put the types of cutting edge, non-chemotherapy medicines used by internists into the hands of the surgeon for the purpose of preventing local recurrence at the earliest possible moment.
Engineering Forward Initiative for Childhood Cancer Therapies: $1,500,000
This multi-disciplinary approach to accelerating discovery of therapies for childhood cancer is made possible by a joint effort of our scientific director Dr. Keller and our Board member, Sunit Rikhi, former VP of the Intel custom foundry. Together, our teams of biologists and engineers will maximize automation and the design of new devices and biomaterials that address challenges in the treatment of cancer as well as prevention of recurrence, ultimately improving outcomes for children with cancer.
A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually
Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical: for tumors in a limb, local control permits limb-sparing procedures; whereas for tumors not in a limb, local control can mean the difference between cure and progression of disease. Our recent published studies suggest that a non-chemotherapy medicine
